Genentech's Herceptin is the first drug to target a cancer-causing genetic defect. It blocks a gene found in 30% of breast-cancer victims. (800) 626-3553
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.